Parkinson Disease
Conditions
Brief summary
This research is studying the use of a new type of standing desk in a small number of people to learn about the user experience for people with Parkinson's disease. 12 4-hour sessions will be performed to test the primary hypothesis that dynamic standing improves gait function compared to static standing and control sitting. This study has 2 phases. Phase 1 will be an open-label study and Phase 2 will be an in-lab randomized controlled trial pilot study. This is phase 1 of the study.
Detailed description
For phase 1, participants will attend up to 12 4-hour sessions using the dynamic standing desk. In addition to these sessions, there will be a clinical assessment at baseline and an outcome session (endpoint assessments). In total, there will be up to 14 sessions per participant. All sessions need to be completed within 6 weeks. At the baseline session, clinical measurements will be collected. These measures will be repeated in the outcome session.
Interventions
DEVICEDynamic Standing Desk
Participants will stand at the desk for 4 hours per session. During each session, the desk will move to prompt the participant to take small steps. Participants will take breaks as needed. Each participant will complete up to 12 sessions in the span of 6 weeks.
Sponsors
University of Michigan
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Parkinson's Disease
Exclusion criteria
* Inability to stand or walk without an assistive device * History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects * Any other history of medical or psychiatric comorbidity, precluding safe participation in the project. * History of symptomatic cardiovascular or pulmonary disease * History of active rheumatic arthritis * History of stroke or other neurologic conditions with significant residual sensorimotor deficits * History of disabling chronic pain syndrome requiring narcotic analgesics * Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) \<24 and significant impairment in activities of daily living) * Venous ulcerative stasis or severe varicosities. * Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gait Speed | Baseline and post-intervention (up to 6 weeks). | Gait speed will be measured during an 8.5-meter forward walking task measured in meters per second. |
| Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III | Baseline and post-intervention (up to 6 weeks). | Clinical assessment that measures motor symptoms in Parkinson's Disease. Higher scores indicates more severe symptoms. Scores range from 0-132. |
| Montreal Cognitive Assessment | Baseline and post-intervention (up to 6 weeks). | Clinical assessment that measures cognition. Higher scores indicate better cognition. Scores range from 0-30. |
| Timed Up and Go | Baseline and post-intervention (up to 6 weeks). | Clinical assessment that measures the time it takes for a participant to stand from a chair, walk 3 meters, turn around, walk back to the chair and sit back down. Higher time indicates increased motor impairment. |
| 5 Times Sit to Stand | Baseline and post-intervention (up to 6 weeks). | Clinical assessment that measures the time it takes for a participant to sit and stand five times. Higher time indicates increased motor impairment. |
Countries
United States
Contacts
CONTACTMiriam Van Emde Boas, DPT
CONTACTChatkaew Pongmala, PhD
PRINCIPAL_INVESTIGATORChatkaew Pongmala, PhD
University of Michigan
Outcome results
None listed